What happened with AORT today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Artivion serves cardiac and vascular surgeons treating diseases of the aorta, the body's main artery, and heart valves. Hospitals and other healthcare facilities buy its products directly or through distributors. Medical devices generate most of its revenue, with aortic stent grafts the largest line and sold mainly outside the United States. Other important products include On-X mechanical heart valves for valve replacement and BioGlue, which surgeons use alongside sutures and staples to help control bleeding during large-vessel repair.
Artivion also earns a substantial share of revenue by processing and preserving donated human heart valves, cardiac patches and blood vessels for implantation. It distributes these tissues to institutions performing valve replacement, cardiac repair and vascular reconstruction. This business depends on the supply of donated tissue and how much can be successfully processed and released for surgery.
Product sales depend on surgeons adopting its devices and on obtaining and maintaining authorization in each market. Availability differs by country. In the United States, its AMDS device has restricted commercial distribution under an FDA humanitarian device exemption for certain acute aortic dissections that impair blood flow; it does not have unrestricted U.S. commercial approval.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Artivion’s results hinge on adoption of aortic devices and demand for cardiac and vascular surgery, so also watch companies absent from this list: Gore, Terumo and Cook in aortic grafts, and LifeNet Health in preserved tissues.
LeMaitre competes with Artivion for vascular and cardiac surgeons’ purchases of grafts, patches and preserved human tissues. Its sales for open surgery are worth watching for demand in this shared market: those procedures accounted for over 95% of LeMaitre’s 2025 net sales.
Medtronic competes for healthcare providers’ purchases of mechanical heart valves and aortic stent grafts, overlapping Artivion’s On-X and aortic stent-graft businesses, which supplied 23% and 36% of its 2025 revenue respectively. Watch Medtronic’s new products in those areas for changes in the alternatives available to Artivion’s customers.
Edwards Lifesciences offers valve-replacement teams alternatives to Artivion’s mechanical valves and some preserved cardiac tissues: surgical tissue valves and valves delivered through a catheter without traditional open-heart surgery. Its surgical tissue-valve sales are the closer comparison, while its catheter-delivered aortic valves accounted for 74% of Edwards’ 2025 net sales.
Abbott competes with Artivion’s On-X mechanical heart valves for purchases by cardiac surgical teams replacing patients’ valves. For Artivion holders, Abbott’s valve offerings matter more than its broad healthcare business; On-X’s distinguishing feature is its approved lower-anticoagulation option for aortic, but not mitral, valves.
BD competes with Artivion for healthcare providers’ purchases of vascular-reconstruction products and, through Bard, surgical sealants. Watch Bard’s sealant offerings against BioGlue, which surgeons use alongside sutures and staples to help control bleeding in adult open repairs of large blood vessels.
AtriCure and Artivion both depend on cardiac surgery volumes and adoption of devices used during open-heart operations: AtriCure sells medical centers devices that treat irregular heart rhythms and manage the left atrial appendage, while Artivion sells surgeons valves, aortic devices and sealants. AtriCure’s sales of disposable surgical ablation devices and AtriClip implants offer a view of this shared demand, though its products also serve minimally invasive procedures.
Abbott Laboratories earningsABT
Abbott’s report can show whether demand and competition in mechanical heart valves are changing for Artivion’s On-X business.
Look for the performance of Abbott’s heart-valve business. Stronger sales would mean hospitals and clinicians are buying more of an alternative, potentially raising competition for On-X. Weaker sales could ease that pressure, but would not prove Artivion gained share; its own On-X sales are needed to tell.
Fed Interest Rate Decision
Artivion’s rate-sensitive debt makes the Fed’s benchmark borrowing rate matter: changes can alter interest paid on its loans and the cash left for medical-device and tissue-preservation operations.
Expected4.0%Last release4.0%
If it comes in above expectations
If the Fed’s rate is higher than expected, interest costs on Artivion’s mostly floating-rate debt may rise, leaving less cash for operations and investment.
If it comes in below expectations
If the Fed’s rate is lower than expected, interest costs on Artivion’s mostly floating-rate debt may ease, leaving more cash for operations and investment.
AtriCure, Inc. earningsATRC
AtriCure’s report will show demand for ablation devices and left atrial appendage clips, offering a read on the cardiac-surgery market Artivion also serves.
Look at sales of disposable ablation devices alongside AtriClip implants. Growth in both would suggest hospitals and clinicians are buying more tools for cardiac procedures, supporting demand in a market Artivion serves too. Weakness would point to softer shared demand, but AtriCure also serves minimally invasive procedures, so the two markets are not identical.
Edwards Lifesciences Corp earningsEW
Edwards Lifesciences’ report will show whether valve-replacement demand is holding up in surgery or shifting toward catheter-delivered valves, a change that matters to Artivion’s valves and preserved tissues.
Compare Edwards Lifesciences’ surgical tissue-valve sales with its catheter-delivered aortic-valve sales; catheter-delivered valves made up 74% of its 2025 net sales. Strong surgical-valve sales would indicate that open valve replacement still has demand. If catheter sales grow while surgical sales weaken, the shift could narrow the market for procedures using Artivion’s mechanical valves and preserved tissues.
LeMaitre Vascular, Inc. earningsLMAT
LeMaitre Vascular’s report will show how demand is moving for grafts, patches, and preserved tissues used in open surgery, a market Artivion also serves.
Focus on LeMaitre Vascular’s sales for open surgery, which accounted for over 95% of its 2025 net sales. Strong sales would show that vascular surgeons and hospitals continue buying these surgical products, supporting a market Artivion serves. Weak sales would point to softer demand, but would not prove Artivion lost share.
Artivion, Inc. earningsThis company
Artivion’s report will show whether sales of aortic stent grafts and On-X products can keep supporting its medical-device business as tissue-preservation services stabilize.
Compare Medical Devices revenue, especially aortic stent grafts and On-X, with Preservation Services revenue, then check gross margin. If device growth broadens and tissue-service revenue stops falling without margin weakening, Artivion’s growth is not resting on products alone; if device growth slows as services keep shrinking and margin weakens, growth depends more heavily on a narrower set of products.
Becton, Dickinson and Co. earningsBDX
If BD’s report sheds light on Bard sealant sales, it will show how demand is moving for products that compete with BioGlue.
If BD reports sales for Bard sealants or related surgical products, compare them with Artivion’s BioGlue business. Growth would mean providers are buying more competing products, potentially increasing pressure on BioGlue; weakness could signal softer demand. BD is broad, so without those product details its overall results cannot settle the sealant question.
